H. Beltran

This paper develops and characterizes B18-94, the first BRN2 inhibitor, showing efficacy in reducing NEPC tumor growth with no toxicity.

This study identifies molecular features of primary prostate cancer and their relation to metastasis using genomic and histopathological analysis.

This study identifies Tribbles 2 as a driver of enzalutamide resistance in prostate cancer by promoting lineage plasticity and neuroendocrine differentiation.

The paper investigates the role of mSWI/SNF complexes in NEPC lineage plasticity using patient data and cell models, finding deregulated subunits and SMARCA4 overexpression linked to aggressive disease.

This study identifies four subtypes of castration-resistant prostate cancer using ATAC-seq and RNA-seq data, revealing novel therapeutic targets and classification for 370 patients.

The paper identifies FOXA1 reprogramming in NEPC and shows its role in maintaining NE lineage features through epigenomic profiling.

The paper quantifies repeat-instability in cancer and normal tissues using proteomic and genomic data, identifying tumor-specific signatures linked to progression and tumorigenic state.